Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.48 |
| ▸ | CES1 | P23141 | 9/20 | 0.47 |
| ▸ | CES2 | O00748 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrapentylammonium SCHEMBL15355495 | 0.78 | SLC22A1 (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| Tetrabuthylammonium SCHEMBL107845 | 0.78 | SLC22A1 (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| Tetrahexylammonium SCHEMBL15355454 | 0.77 | SLC22A1 (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL6736795 | 0.76 | CES2 (0.45) | FAAHCES1CES2MEN1CYP1A2 | |
| Decanoic Acid SCHEMBL6565571 | 0.75 | FAAH (0.59) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL2552104 | 0.75 | FAAH (0.48) | FAAHCES1CES2MEN1CYP1A2 | |
| Heptanoate SCHEMBL6563286 | 0.75 | FAAH (0.59) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL11435310 | 0.75 | DNM1 (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| Myristic Acid SCHEMBL6563262 | 0.75 | FAAH (0.59) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3777644 | 0.75 | DNM1 (0.54) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417384-B1 | SUPERIOR IMAGING AND VISUALIZATION OF NEOPLASTIC LESIONS; TUMOR-SPECIFIC CYTOTOXIC CANCER THERAPY, DIAGNOSIS AND TREATMENT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-07-09 | — | — | US | disclosed |
| US-20020065429-A1 | Radioiodinated phospholipid ether analogs and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-05-30 | — | — | US | disclosed |
| US-6255519-B1 | RADIOLABELLED PHARMACEUTICALS AND BIOLOGICAL PROBES UEFUL IN CANCER DIAGNOSIS AND TREATMENT; IMAGING TECHNOLOGY | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2001-07-03 | — | — | US | disclosed |
| EP-0648130-B1 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING | UNIV MICHIGAN (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5795561-A | TUMOR SPECIFIC; MEDICAL DIAGNOSIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1998024480-A1 | RADIOIODINATED PHOSPHOLIPID ETHER ANALOGS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0648130-A1 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING | THE UNIVERSITY OF MICHIGAN (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5347030-A | Radioiodinated phospholipid ether analogues and methods of using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0648130-A4 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING. | UNIV MICHIGAN (US) | 1994-01-26 | — | — | EP | disclosed |
| US-5093042-A | Site-specific for liver; diagnosis of metastatic cancer | THE UNIVERSITY OF MICHIGAN (US) | 1992-03-03 | — | — | US | disclosed |
| US-5087721-A | Tumor-specific; for diagnosis and therapy | THE UNIVERSITY OF MICHIGAN (US) | 1992-02-11 | — | — | US | disclosed |
| US-5077035-A | Scintigraphic imaging of brain; Alzheimer*s diagnosis | THE UNIVERSITY OF MICHIGAN (US) | 1991-12-31 | — | — | US | disclosed |
| WO-1991017776-A1 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING | THE UNIVERSITY OF MICHIGAN (US) | 1991-11-28 | — | — | WO | disclosed |
| US-4965391-A | Tumor specific | THE UNIVERSITY OF MICHIGAN (US) | 1990-10-23 | — | — | US | disclosed |
| US-4957729-A | CONTRAST | THE UNIVERSITY OF MICHIGAN (US) | 1990-09-18 | — | — | US | disclosed |
| US-4933157-A | IMAGING AGENTS FOR ADRENAL GLANDS | THE UNIVERSITY OF MICHIGAN (US) | 1990-06-12 | — | — | US | disclosed |
| US-4925649-A | Radioiodinated diacylglycerol analogues and methods of use | THE UNIVERSITY OF MICHIGAN (US) | 1990-05-15 | — | — | US | disclosed |
| US-4873075-A | SITE-SPECIFIC TO LIVER AND HEPATOCYTE; SCINTIGRAPHY IMAGING | THE UNIVERSITY OF MICHIGAN (US) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065429-A1 | Radioiodinated phospholipid ether analogs and methods of using the same | PHOSPHO1, CDIPT, LPCAT3 | FAAH 1181/4885CES1 624/4885CES2 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.